Euglycemic DKA in MODY Patient: Empagliflozin to Blame.

Angela Magdaleno  
*Lehigh Valley Health Network, angela.magdaleno@lvhn.org*

Sandhya Venkataraman DO  
*Lehigh Valley Health Network, Sandhya.Venkataraman@lvhn.org*

Gretchen Perilli MD  
*Lehigh Valley Health Network, gretchen_a.perilli@lvhn.org*

Follow this and additional works at: [http://scholarlyworks.lvhn.org/medicine](http://scholarlyworks.lvhn.org/medicine)

Published In/Presented At  

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Euglycemic DKA in MODY Patient: Empagliflozin to Blame

Angela Magdaleno, DO, Sandhya Venkataraman, DO and Gretchen Perilli, MD
Lehigh Valley Health Network, Allentown, Pennsylvania

BACKGROUND

- Diabetic ketoacidosis (DKA) occurs when the body’s requirements for insulin are higher than the insulin available for use, resulting in lipolysis, ketogenesis, and ketoacidosis
- DKA is classically associated with Type 1 diabetes mellitus (DM), but can occur in any patient with diabetes
- Euglycemic DKA is defined by ketosis, metabolic acidosis, and a blood glucose level less than 200 mg/dL
- Euglycemic DKA is concerning as it can be easily misdiagnosed and mistreated
- Few cases have demonstrated a possible relationship between empagliflozin and euglycemic DKA
- Empagliflozin is a sodium glucose co-transporter (SLGT-2) inhibitor in the proximal convoluted tubule of the kidney to reduce reabsorbed filtered glucose, resulting in decreased serum glucose levels.

CASE PRESENTATION

42 year old female with mature onset diabetes of the young (MODY) type 2 presented to the emergency room with complaints of nausea, vomiting and epigastric abdominal pain worsening over four days. She was diagnosed with gestational DM at age 34 and post-partum was unsuccessfully treated with a variety of oral medications. She underwent testing which revealed a glucokinase mutation consistent with MODY type 2. Recently, she was started on empagliflozin-linagliptin in addition to a diet of less than 60 grams of carbohydrates per day. On admission, imaging was unrevealing, and she was diagnosed with gastroenteritis. Her serum glucose was 106 mg/dL, potassium was 4.6 mmol/L, bicarbonate was 21 mmol/L, anion gap was 14, and lipase was normal. Urinalysis revealed glucose of 500 mg/dL, ketones > 160 mg/dL, and specific gravity > 1.030. Venous blood gas revealed metabolic acidosis. Beta hydroxybutyrate was 2.71 mmol/L. The patient was diagnosed with euglycemic DKA. Endocrinology discontinued empagliflozin, emphasizing that the only treatment required for MODY type 2 is diet restriction. Her symptoms improved, labs normalized, and she was discharged.

DISCUSSION

- This case demonstrates a deadly combination of inappropriate SGLT-2 inhibitor use causing decreased serum glucose levels in a MODY type 2 patient resulting in euglycemic DKA
- MODY Type 2 results from a defective glucokinase enzyme, therefore increased serum glucose levels are required to trigger insulin secretion
- Patients with MODY Type 2 often present with mild fasting hyperglycemia, which is required to stimulate insulin secretion
- In this case, empagliflozin resulted in decreased serum glucose and increased glucosuria. As a result, the body’s demands for insulin were higher than the amount of insulin being secreted due to defective glucokinase enzyme, inducing DKA.

Table 1 - Genetic and Clinical Characteristics of MODY Subgroups

<table>
<thead>
<tr>
<th>MODY 1</th>
<th>MODY 2</th>
<th>MODY 3</th>
<th>MODY 4</th>
<th>MODY 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetics</td>
<td>HNF-4α</td>
<td>Glucokinase</td>
<td>HNF-3</td>
<td>P/TF-1</td>
</tr>
<tr>
<td>Prevalence</td>
<td>5%</td>
<td>15%</td>
<td>30%</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Severity</td>
<td>Progressive IGT</td>
<td>MODCa/moric hypoglycemia</td>
<td>Progressive IGT</td>
<td>Progressive IGT</td>
</tr>
<tr>
<td>Onset</td>
<td>12-28 years</td>
<td>Birth</td>
<td>12-28 years</td>
<td>14-40 years</td>
</tr>
<tr>
<td>Microvascular Complications</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Treatment</td>
<td>Progressive need</td>
<td>Pregnancy</td>
<td>Progressive need</td>
<td>Progressive need</td>
</tr>
</tbody>
</table>

Figure: Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development of full-blown episodes of euglycemic DKA. Image References:
1. Pediatr. (Rio J.) vol.83 no.5 supple.0 Porto Alegre Nov. 2007

© 2017 Lehigh Valley Health Network

610-402 CARE LVHN.org